These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 26522003

  • 1. Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach.
    Garcia Vicente AM, Soriano Castrejón A, Amo-Salas M, Lopez Fidalgo JF, Muñoz Sanchez MM, Alvarez Cabellos R, Espinosa Aunion R, Muñoz Madero V.
    Rev Esp Med Nucl Imagen Mol; 2016; 35(3):152-8. PubMed ID: 26522003
    [Abstract] [Full Text] [Related]

  • 2. Basal ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer.
    García Vicente AM, Soriano Castrejón Á, López-Fidalgo JF, Amo-Salas M, Muñoz Sanchez Mdel M, Álvarez Cabellos R, Espinosa Aunión R.
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1804-13. PubMed ID: 26156534
    [Abstract] [Full Text] [Related]

  • 3. Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.
    García Vicente AM, Amo-Salas M, Relea Calatayud F, Muñoz Sánchez Mdel M, Pena Pardo FJ, Jiménez Londoño GA, Álvarez Cabellos R, Espinosa Aunión R, Soriano Castrejón Á.
    Clin Nucl Med; 2016 Jul; 41(7):e313-22. PubMed ID: 26953659
    [Abstract] [Full Text] [Related]

  • 4. Intratumoral heterogeneity in 18F-FDG PET/CT by textural analysis in breast cancer as a predictive and prognostic subrogate.
    Molina-García D, García-Vicente AM, Pérez-Beteta J, Amo-Salas M, Martínez-González A, Tello-Galán MJ, Soriano-Castrejón Á, Pérez-García VM.
    Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
    [Abstract] [Full Text] [Related]

  • 5. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S, Tanriverdi O, Karapolat I, Demir L, Bayoglu V, Can A, Akyol M, Yilmaz Y, Oktay Tarhan M.
    J BUON; 2016 Jul; 21(6):1410-1418. PubMed ID: 28039701
    [Abstract] [Full Text] [Related]

  • 6. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.
    Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC.
    Cancer; 2015 Nov 15; 121(22):3965-74. PubMed ID: 26249241
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J, Fernandez I, Del Hoyo O, Navarro A, Gomez-Iturriaga A, Pijoan JI, Martinez-Indart L, Escudero J, Gomez-Suarez J, de Zarate RO, Perez JF, Bilbao P, Rades D.
    Clin Transl Oncol; 2017 Nov 15; 19(11):1337-1349. PubMed ID: 28540535
    [Abstract] [Full Text] [Related]

  • 8. Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT.
    Jeong YJ, Jung JW, Cho YY, Park SH, Oh HK, Kang S.
    Nucl Med Rev Cent East Eur; 2017 Nov 15; 20(1):32-38. PubMed ID: 28198519
    [Abstract] [Full Text] [Related]

  • 9. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, Lee J.
    J Nucl Med; 2012 Sep 15; 53(9):1337-44. PubMed ID: 22870824
    [Abstract] [Full Text] [Related]

  • 10. 18F-FDG PET/CT as predictor of tumour biology and prognosis in epithelial ovarian carcinoma.
    González García B, García Vicente AM, Jiménez Londoño GA, Pena Pardo FJ, Bellón Guardia ME, Talavera Rubio MP, Palomar Muñoz A, Gómez Herrero P, Soriano Castrejón ÁM.
    Rev Esp Med Nucl Imagen Mol; 2017 Sep 15; 36(4):233-240. PubMed ID: 28284928
    [Abstract] [Full Text] [Related]

  • 11. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
    Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M.
    Radiat Oncol; 2016 Mar 16; 11():43. PubMed ID: 26984385
    [Abstract] [Full Text] [Related]

  • 12. Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?
    De Cicco C, Gilardi L, Botteri E, Fracassi SL, Di Dia GA, Botta F, Prisco G, Lombardo D, Rotmensz N, Veronesi U, Paganelli G.
    Breast; 2013 Feb 16; 22(1):39-43. PubMed ID: 22704459
    [Abstract] [Full Text] [Related]

  • 13. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH, Lee SW, Jeong SY, Song BI, Chae YS, Ahn BC, Lee J.
    AJR Am J Roentgenol; 2015 Oct 16; 205(4):878-85. PubMed ID: 26204115
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.
    Biomed Mater Eng; 2014 Oct 16; 24(6):3091-103. PubMed ID: 25227018
    [Abstract] [Full Text] [Related]

  • 15. The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer.
    Diao W, Tian F, Jia Z.
    Eur J Radiol; 2018 Aug 16; 105():1-7. PubMed ID: 30017264
    [Abstract] [Full Text] [Related]

  • 16. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S, Kadoya T, Okada M.
    Breast; 2013 Oct 16; 22(5):958-63. PubMed ID: 23756383
    [Abstract] [Full Text] [Related]

  • 17. Global heterogeneity assessed with 18F-FDG PET/CT. Relation with biological variables and prognosis in locally advanced breast cancer.
    Tello Galán MJ, García Vicente AM, Pérez Beteta J, Amo Salas M, Jiménez Londoño GA, Pena Pardo FJ, Soriano Castrejón ÁM, Pérez García VM.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Oct 16; 38(5):290-297. PubMed ID: 31427247
    [Abstract] [Full Text] [Related]

  • 18. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC.
    Oncologist; 2017 May 16; 22(5):526-534. PubMed ID: 28377466
    [Abstract] [Full Text] [Related]

  • 19. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY, Guo Z, Sun J, Yang WP, Li TR.
    Zhonghua Zhong Liu Za Zhi; 2018 Jul 23; 40(7):528-533. PubMed ID: 30060362
    [Abstract] [Full Text] [Related]

  • 20. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
    Yue Y, Cui X, Bose S, Audeh W, Zhang X, Fraass B.
    Breast Cancer Res Treat; 2015 Oct 23; 153(3):607-16. PubMed ID: 26346756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.